	US 12,116,346 B2
	Human plasma kallikrein inhibitors
Pravin L. Kotian, Hoover, AL (US); Yarlagadda S. Babu, Birmingham, AL (US); Minwan Wu, Vestavia Hills, AL (US); Venkat R. Chintareddy, Vestavia Hills, AL (US); V. Satish Kumar, Birmingham, AL (US); and Weihe Zhang, Vestavia Hills, AL (US)
Assigned to BioCryst Pharmaceuticals, Inc., Durham, NC (US)
Filed by BioCryst Pharmaceuticals, Inc., Durham, NC (US)
Filed on Apr. 18, 2023, as Appl. No. 18/136,025.
Application 18/136,025 is a continuation of application No. 17/543,929, filed on Dec. 7, 2021, granted, now 11,708,333.
Application 17/543,929 is a continuation of application No. 16/845,833, filed on Apr. 10, 2020, granted, now 11,230,530, issued on Jan. 25, 2022.
Application 16/845,833 is a continuation of application No. 16/400,798, filed on May 1, 2019, granted, now 10,689,346, issued on Jun. 23, 2020.
Application 16/400,798 is a continuation of application No. 15/977,129, filed on May 11, 2018, granted, now 10,329,260, issued on Jun. 25, 2019.
Application 15/977,129 is a continuation of application No. 15/123,059, granted, now 10,125,102, issued on Nov. 13, 2018, previously published as PCT/US2015/019535, filed on Mar. 9, 2015.
Claims priority of provisional application 61/981,515, filed on Apr. 18, 2014.
Claims priority of provisional application 61/949,808, filed on Mar. 7, 2014.
Prior Publication US 2024/0150296 A1, May 9, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 231/14 (2006.01); C07D 401/04 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 403/04 (2006.01); C07D 403/12 (2006.01); C07D 405/12 (2006.01); C07D 413/04 (2006.01); C07D 413/12 (2006.01); C07D 417/12 (2006.01)

CPC C07D 231/14 (2013.01) [C07D 401/04 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 403/12 (2013.01); C07D 405/12 (2013.01); C07D 413/04 (2013.01); C07D 413/12 (2013.01); C07D 417/12 (2013.01)]

26 Claims

1. A compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of: